Elsayed S. Moubarak: Evaluating Established and Emerging Biomarkers in Hemophilia A and B Management
Elsayed S. Moubarak, Member of NEGIDA Corporation, Researcher at Research Medical Center, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
”I’m pleased to share that our recent review article has been published in ASIDE Internal Medicine.
In this narrative review, we explored established and emerging biomarkers in Hemophilia A and B, highlighting their diagnostic, prognostic, and therapeutic implications in the era of extended half-life therapies, non-factor treatments, and gene therapy.
The review discusses:
- FVIII/FIX activity assays and inhibitor testing
- Genotyping approaches
- Global hemostasis assays
- Pharmacokinetic-guided prophylaxis
- Novel inflammatory and angiogenic markers linked to arthropathy
I am honored to contribute as Second Author and Corresponding Author on this work.
Grateful to my co-authors for their collaboration and dedication.”
Title: Biomarkers in Hemophilia: Diagnostic, Prognostic, and Treatment-Selection Utility: A Narrative Review of the Literature
Authors: Dalia Atef Abouda, Elsayed S. Moubarak, Fatma ElBadrawy, Malak A. Hassan, Mohamed Mohsen Helal, Abdallah M. Ibrahim, Hassan H. Eladl, Mohammad Mahadin, Mohamed Elsaid
Read the Full Article on ASIDE Internal Medicine Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 3, 2026, 14:28Stephanie Matz: Recognizing the Incredible Social Work Team at Hemophilia of Georgia
-
Mar 3, 2026, 14:21Danny Hsu: The 2nd THANZ Webinar Series To Bring Timely Updates in Thrombosis and Hemostasis
-
Mar 3, 2026, 14:10Kalyan Roy: Understanding Erythroblastosis Fetalis
-
Mar 3, 2026, 14:04Najah Sampson: Understanding Key Risk Factors and Symptoms of VTE
-
Mar 3, 2026, 09:10From Fear to Freedom: Hemophilia A, Emicizumab Prophylaxis, and the Rewriting of a Childhood
-
Mar 3, 2026, 09:01Amy Owen-Wyard: A Life Should Not Have a Price Tag Attached to Its Rarity
-
Mar 3, 2026, 08:54Kanishk Kumar: Novel Complement Inhibitors and Next-Generation Therapies as Driving Momentum for aHUS
-
Mar 3, 2026, 08:48Megan Adediran: Redefining Rare Diseases in Nigeria’s Healthcare System
-
Mar 3, 2026, 08:18Peter Zdziarski: A Brighter Future for Glanzmann Thrombasthenia Through Gene Therapy